ASX Announcements
2011 — Quarter 1 |
---|
Code | Title | Date | ||
---|---|---|---|---|
ACR | Axiron Launched by Eli Lilly in the United States | 31/03/2011 | ||
ACR | Acrux Declares First Dividend of 60 cents per share | 24/03/2011 | ||
ACR | Appendix 3B | 16/03/2011 | ||
ACR | Acrux Files Half Year Results | 24/02/2011 | ||
ACR | Half Year Accounts and Appendix 4D | 24/02/2011 | ||
ACR | Appendix 3B | 15/02/2011 | ||
ACR | Ceasing to be a substantial holder | 04/02/2011 | ||
ACR | Appendix 4C - Quarterly Cash Flow Report | 31/01/2011 | ||
ACR | Appendix 3B | 21/01/2011 | ||
ACR | Regulatory update on animal health product | 13/01/2011 |
2011 — Quarter 2 |
---|
Code | Title | Date | ||
---|---|---|---|---|
ACR | Acrux receives marketing approval for Ellavie in Sweden | 27/05/2011 | ||
ACR | Appendix 3B | 12/05/2011 | ||
ACR | Positive European opinion for first animal health product | 10/05/2011 | ||
ACR | Appendix 4C - Quarterly Cash Flow Report | 29/04/2011 | ||
ACR | Appendix 3B | 07/04/2011 |
2011 — Quarter 3 |
---|
Code | Title | Date | ||
---|---|---|---|---|
ACR | Market Update | 28/09/2011 | ||
ACR | SandP Indices Announces September Quarterly Rebalance | 09/09/2011 | ||
ACR | Change in substantial holding | 08/09/2011 | ||
ACR | SandP Indices Announces September SP/ASX 200 Rebalance | 02/09/2011 | ||
ACR | Change of Director`s Interest Notice | 31/08/2011 | ||
ACR | Final Director`s Interest Notice | 31/08/2011 | ||
ACR | Acrux founder Barrie Finnin retires from the board | 31/08/2011 | ||
ACR | Acrux not required to file quarterly cash flow reports | 31/08/2011 | ||
ACR | Eli Lilly Report to Acrux Investment Community | 23/08/2011 | ||
ACR | 2010/11 Financial Results | 23/08/2011 | ||
ACR | Acrux Reports Full Year Profit of $57 Million | 23/08/2011 | ||
ACR | Appendix 4E and Financial Report for the year ended 30 June | 23/08/2011 | ||
ACR | Change in substantial holding | 02/08/2011 | ||
ACR | Appendix 4C - Quarterly Cash Flow Report | 29/07/2011 | ||
ACR | Change in substantial holding | 18/07/2011 | ||
ACR | Eli Lilly provides feedback on initial uptake of Axiron | 01/07/2011 |
2011 — Quarter 4 |
---|
Code | Title | Date | ||
---|---|---|---|---|
ACR | Orion manufacturing facility update | 01/12/2011 | ||
ACR | Orion manufacturing facility, Finland | 24/11/2011 | ||
ACR | 2011 AGM Results of Meeting | 23/11/2011 | ||
ACR | 2011 AGM CEO Presentation | 23/11/2011 | ||
ACR | 2011 AGM Chairman`s Address | 23/11/2011 | ||
ACR | Change of Director`s Interest Notice | 04/11/2011 | ||
ACR | 2026 patent for Axiron granted by Australian patent office | 03/11/2011 | ||
ACR | 2011 AGM Notice and Proxy Form | 21/10/2011 | ||
ACR | 2011 Annual Report | 21/10/2011 | ||
ACR | Marketing authorisation for Recuvyra granted in Europe | 13/10/2011 |